Improving asthma outcomes in large populations
|
|
- Winfred Hoover
- 5 years ago
- Views:
Transcription
1 Current perspectives Improving asthma outcomes in large populations Michael Schatz, MD, MS, and Robert S. Zeiger, MD, PhD San Diego, Calif This article summarizes our experience using administrative, survey, and telephone information to define asthma severity, impairment, risk, and quality of care in our large Kaiser Permanente population. Our data suggest that the 2-year Healthcare Effectiveness Data and Information Set definition of persistent asthma is a good surrogate for survey-defined persistent asthma, and thus it would be reasonable to direct asthma population management and quality-of-care assessments at patients with Healthcare Effectiveness Data and Information Set defined persistent asthma for 2 years in a row. For population management, the numbers of short-acting b-agonist (SABA) canisters dispensed and validated tools on mail or telephone surveys have been used to assess asthma impairment. Algorithms based on pharmacy data (SABA canister and oral corticosteroid dispensings and prior emergency hospital care) have been used to assess the risk domain of asthma control. The asthma medication ratio (controllers divided by controllers plus SABAs) has been shown to be related to improved outcomes and is recommended as an asthma quality-of-care marker. It is hoped that outreach to patients and providers based on these indicators will improve asthma outcomes in patients cared for in individual practices, as well as in large health plans. (J Allergy Clin Immunol 2011;128:273-7.) Key words: Asthma, population management, quality of care, administrative data, asthma control Discuss this article on the JACI Journal Club blog: Asthma is a common chronic medical condition that is associated with substantial individual morbidity and cost to society. 1,2 Recent surveys show that more than 40% of both adults 3 and children 4 in the United States report uncontrolled asthma. Explanations for this high prevalence of uncontrolled asthma include that asthmatic patients are not seeking medical attention appropriately, that they are not receiving optimal care when seen, or both. The traditional approach to improving disease From the Department of Allergy, Kaiser Permanente Medical Center. Disclosure of potential conflict of interest: M. Schatz has consulted for Amgen, Merck, and GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline, and Merck. R. S. Zeiger declares that he has no relevant conflict of interest. Received for publication February 1, 2011; revised March 18, 2011; accepted for publication March 24, Available online April 17, Reprint requests: Michael Schatz, MD, MS, Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Blvd, San Diego, CA michael. x.schatz@kp.org /$36.00 Ó 2011 American Academy of Allergy, Asthma & Immunology doi: /j.jaci Abbreviations used ACT: Asthma Control Test AQLQ: Mini-Asthma Quality of Life Questionnaire ATAQ: Asthma Therapy Assessment Questionnaire EPR3: National Asthma Education and Prevention Program Guidelines for the Management of Asthma Expert Panel Report 3 HEDIS: Healthcare Effectiveness Data and Information Set OR: Odds ratio SABA: Short-acting b-agonist outcomes has been by one-on-one physician-patient interactions, but this alone cannot correct the above 2 problems. Computerization of medical utilization and claims data ( administrative data ) has allowed 2 more recent approaches for asthma that deal with (1) population management and (2) asthma quality of care. By initiating outreach to patients with uncontrolled asthma and identifying providers whose management practices could be improved, these approaches could address the above 2 factors (patients not seeking care and inadequate quality of care) potentially related to the high prevalence of uncontrolled asthma in this country. For population management, patients with inadequately controlled asthma are identified based on administrative data criteria, and targeted interventions by mail, telephone, or in-person visits are implemented. Information obtained from mailed surveys or by telephone can supplement the administrative data and increase the sensitivity, specificity, or both of the information obtained. For asthma quality of care, performance measures derived from administrative data are used by managed care organizations and others to improve the performance of their providers, with the expectation that improved performance on the measures will lead to improved asthma outcomes. 5 From this perspective, we would like to summarize our experience using administrative, survey, and telephone information to define asthma severity, impairment, risk, and quality of care in our large Kaiser Permanente population. We hope that we and others can use this information to improve outcomes in patients with asthma. POPULATION MANAGEMENT Persistent asthma Although patients with intermittent asthma can suffer severe exacerbations, 6 most outreach efforts in population management (and quality of care assessments) are directed at patients with persistent asthma. The recent National Asthma Education and Prevention Program Guidelines for the Management of Asthma Expert Panel Report 3 (EPR3) defines persistent asthma on the basis of symptom frequency and impact, rescue therapy use, pulmonary function, and exacerbation history
2 274 SCHATZ AND ZEIGER AUGUST 2011 The most widely used administrative data marker of persistent asthma is the Healthcare Effectiveness Data and Information Set (HEDIS) definition, 7 which entails meeting 1 or more of the following criteria in a 12-month period: (1) 4 or more asthma medication dispensings, (2) 1 or more emergency department visits or hospitalizations with a principal diagnosis of asthma, or (3) 4 or more asthma outpatient visits with 2 or more asthma medication dispensings. After we demonstrated a relationship between the number of consecutive years of HEDIS qualification and markers of persistent asthma, 8 the National Committee for Quality Assurance modified its specification of the HEDIS persistent asthma population to require meeting the above administrative data criteria for persistent asthma for both the premeasurement year and the measurement year (the year the measure is being assessed). 7 Only limited data have explored the relationship of the (1 or 2 years) HEDIS administrative data definition of persistent asthma to a more clinical definition. We have recently explored this relationship in a cohort of almost 3000 patients with HEDISdefined persistent asthma in 2006 who completed a mailed survey in The survey defined persistent asthma based on EPR3 guidelines, 6 with 1 addition (regular controller therapy was considered indicative of persistent asthma) and 1 deletion (pulmonary function could not be assessed). We found that nearly 92% of patients with HEDIS-defined persistent asthma in 2006 had survey-defined persistent asthma in We also found that patients who requalified for having HEDIS-defined persistent asthma in 2007 were more likely (P <.0001) to report survey-persistent asthma (97%) than patients who did not requalify for having HE- DIS-persistent asthma in 2007 (82%). 9 These data suggest a good concordance between the HEDIS administrative data definition of persistent asthma and a more clinically defined (survey) definition, especially using the 2-year HEDIS definition. Impairment EPR3 defines 2 separate domains of asthma severity and control. 6 Asthma impairment is defined by EPR3 as the frequency and intensity of symptoms and functional limitations the patient is currently experiencing or has recently experienced. This domain of asthma control includes rescue therapy use. We have identified asthma impairment on a population basis by means of (1) development and validation of a rescue therapy scale based on the number of canisters of short-acting b-agonists (SABAs) dispensed in a 12-month period and (2) administration of the Asthma Control Test (ACT) on automated telephone calls. SABA long-term control scale. The 4-level scale based on canisters of SABAs dispensed over a 12-month period (0-2, 3-6, 7-12, and >12) was validated in a random sample of 2250 Kaiser Permanente patients aged 18 to 56 years with HEDISdefined persistent asthma and a separate sample of 62,369 members aged 18 to 56 years with persistent or intermittent asthma. 10 A factor analysis performed on information obtained in the former sample by surveys that included the mini-asthma Quality of Life Questionnaire (AQLQ), the Asthma Therapy Assessment Questionnaire (ATAQ), and the Asthma Outcomes Monitoring Survey showed loading of the 4-level SABA scale on the symptom control factor. 10 In addition, impairment, as measured by these validated questionnaires, was linearly related to the 4-level scale (Fig 1). 10 The prospective validity of the FIG 1. Relationship of the 4-level SABA scale (number of canisters dispensed in a 12-month period) to mean scores on patient-reported outcome tools. AOMS, Asthma Outcomes Monitoring Survey (higher values indicate more symptoms); AQLQ, Mini-Asthma Quality of Life Questionnaire (higher values indicate better quality of life); ATAQ, Asthma Therapy Assessment Questionnaire (higher values indicate more control problems). All P < Data are from Schatz et al. 10 FIG 2. Relationship of the 4-level SABA scale (number of canisters dispensed in a 12-month period) to the incidence (as a percentage) of subsequent asthma exacerbations, as defined by asthma hospitalization or emergency department visit (Hosp/ED) or any oral corticosteroid dispensing (Steroids). All P < Data are from Schatz et al. 10 scale was tested in the larger sample by assessing the relationship of the scale value during 1 year to emergency hospital care or oral corticosteroid dispensings the following year. A significant linear relationship was also seen between this SABA scale and the subsequent risk of exacerbations (Fig 2). 10 Telephone administration of the ACT. The ACT was completed during automated telephone calls using speech-recognition technology by 2244 patients with physician-diagnosed asthma. 11 Convergent validity was demonstrated by relationships of the ACT score to smoking (lower in smokers) and to patient-described recent course of asthma (lower in patients with a worse course of asthma). Predictive validity was demonstrated by the relationship of the ACT score to subsequent exacerbations and SABA dispensings. After adjusting for demographic characteristics, an ACT score of 15 or less was associated with a significantly increased 12-month risk of emergency hospital care (odds ratio [OR], 2.5; 95% CI, ), any oral corticosteroid dispensing (OR, 2.6; 95% CI, ), and more than 6 canisters of SABAs dispensed (OR, 6.8; 95% CI, ) compared with patients with a score of 20 or greater. 11 An ACT score of 16 to 19 was not associated with a significantly increased risk of subsequent emergency hospital care but was associated with an increased risk of subsequent oral corticosteroid dispensing (OR, 1.7; 95% CI, ) and dispensing of more than 6 canisters of SABAs (OR, 3.1; 95% CI, ). 11
3 VOLUME 128, NUMBER 2 SCHATZ AND ZEIGER 275 TABLE I. Administrative data algorithms for identifying patients at increased risk of subsequent asthma exacerbations Three-level scale 12 Four-level scale 13 Predictors Point allocation SABA dispensings in past year 1 for >_ 14 1 for for > 13 Oral corticosteroid dispensings 1 for any 1 for > 2 in past year Emergency/hospital care in past year 2 Not used Intensity scale level Positive predictive value (%) in testing set by level (0 points) 4.0 (0 points) (1 point) 6.4 (1 point) (>_2 points) 12.4 (2 points) 4 Not applicable 26.8 (3 points) Risk Asthma risk is defined by the EPR3 to include the risk of future exacerbations. 6 We have used both administrative data and survey data to try to identify patients at risk of experiencing future exacerbations. Administrative data. We have developed 2 administrative data algorithms for identifying patients at increased risk of subsequent asthma exacerbations (Table I). 12,13 The first was a 3-level scale developed by using prior emergency department visits and hospitalizations (emergency hospital care) and pharmacy data. This algorithm identified a high-risk group approximately 3 times more likely than other patients to experience a subsequent exacerbation. 12 The second was a 4-level scale based only on pharmacy data that identified a high-risk group more than 6 times more likely to require emergency hospital care than patients in the lowest risk group (Table I). 13 However, comparison of the predictive properties of the 2 schemes suggested that the algorithm including prior emergency hospital care provided a more robust prediction and would thus be recommended if that information was available. 13 As noted above, the number of canisters of SABAs dispensed in a 12-month period is itself related to subsequent exacerbations, but the predictive properties of this SABA scale versus the other 2 algorithms have not been specifically compared. Survey data. In our initial studies we showed that certain levels of increased asthma impairment identified on mailed surveys by using the ATAQ asthma control tool or the AQLQ asthma-specific quality-of-life tool were significantly associated with subsequent emergency hospital care. 14,15 More recently, we have found that low scores on 3 validated questionnaire tools that reflect asthma impairment (ACT score <16, AQLQ score <_4.7, and Asthma Impact Survey score >60) administered on mailed surveys were each related to subsequent exacerbations above and beyond a history of prior exacerbations. 16 These data also showed that each of the 3 tools provided similar predictive power (OR, 1.3) and were not independent of each other in their relationships to subsequent exacerbations. 16 These observations would suggest that any of the 3 tools could be used in addition to a history of prior exacerbations to improve the prediction of subsequent exacerbations, but there is no reason to use more than 1 of these tools to do so. QUALITY OF CARE The most widely used asthma administrative data quality-ofcare measure is the one developed by the National Committee for Quality Assurance to evaluate the performance of health plans, the HEDIS measure. 7 This measure identifies patients with persistent asthma based on the administrative data criteria described above and then determines the proportion of these patients who receive at least 1 asthma controller medication dispensing the following year. Although used for approximately a decade, few studies have attempted to validate the HEDIS measure as being associated with improved subsequent outcomes. One study in children demonstrated such a relationship, 17 but 3 studies in children and adults failed to show that improved performance on this measure is associated with improved asthma outcomes The lack of a relationship of the HEDIS asthma measure to improved outcomes has led to the search for an improved asthma quality-of-care measure based on administrative data that would be associated with improved outcomes. The medication ratio measure has been defined from computerized pharmacy data as the ratio of controllers to total asthma medications (controllers plus relievers) dispensed in a 12-month period. We initially showed that patients with a medication ratio of 0.5 or greater were significantly (P <.0001) less likely (4.5%) than patients with a ratio of less than 0.5 (8.3%) to experience emergency hospital care the following year. 21 We then reported that patients with a medication ratio of 0.5 or greater reported significantly better asthma quality of life and fewer asthma control problems than patients with a ratio of less than Subsequently, several other studies 19,20,23 have confirmed the relationship between a medication ratio of 0.5 or greater and a reduced likelihood of subsequent asthma exacerbations. Thus because it has been consistently associated with improved outcomes, the medication ratio might be a better administrative data measure of asthma quality of care than the HEDIS any controller measure. The number of SABAs dispensed is even more strongly related to subsequent asthma exacerbations than the medication ratio measure. 23 However, the medication ratio measure has one advantage over SABA dispensings as a quality-of-care marker. The SABA measure does not account for severity or the attempt to appropriately use controllers. A patient with severe treated disease might still require high levels of SABAs, but a high medication ratio at least reflects an attempt to use controllers to manage the illness. This would further support the use of the medication ratio measure as an administrative data asthma quality-of-care marker. DISCUSSION The research described above shows that administrative and survey data can be used to reflect asthma severity, impairment, risk, and quality of care in large populations. A strength of these studies is that they were performed in a real-world setting. However, an important issue regarding these studies is their generalizability to other populations. This is especially relevant regarding racial, ethnic, and socioeconomic status because these disparities have well-documented effects on asthma care and outcomes at Kaiser Permanente 24 and elsewhere. 25,26 Our patients are demographically similar to the overall southern California community (Steve Derose, MD, unpublished data, October 2005), and administrative data not depending on survey responses should reflect this generalizability. However, survey data might reflect a more select population. For example, respondents in
4 276 SCHATZ AND ZEIGER AUGUST 2011 TABLE II. Identifying patients for targeted intervention who are at high risk of asthma exacerbations or uncontrolled impairment based on administrative or survey data Asthma exacerbations Level 3 in 3-level algorithm (see Table I) Level 4 in 4-level algorithm (see Table I) >6 SABA canister dispensings in a 12-mo period ACT score <16 ATAQ score >_2 Asthma Impact Survey score >60 AQLQ score <_4.7 Asthma impairment >6 SABA canister dispensings in a 12-mo period ACT score by telephone or survey <20 ATAQ score by survey >0 our most recent survey study had higher socioeconomic characteristics (based on census block assessments) than nonrespondents, 9 and a majority (54%) were white. 16 We have also studied primarily younger patients (<_64 years), and recent studies suggest that patients aged 65 years and older might have worse short- and long-term asthma control than younger patients. 27 Studies like ours in large populations, such as Medicaid and Medicare patients, would test the generalizability of our findings to more demographically, racially, and socioeconomically diverse populations. Pending studies in broader populations, we believe the data summarized in this article have the following implications for large populations similar to ours. First, it would be reasonable to direct asthma population management and quality-of-care assessments at patients with HEDIS-defined persistent asthma for 2 years in a row. If 2 years of data were not available, qualification based on 1 year could be used. Patients at high risk of exacerbations could be identified from administrative or survey data in several ways (Table II). In addition, patients with evidence of poor asthma control based on the impairment domain can also be identified in several ways (Table II). Once identified, it would be hoped that targeted interventions would improve asthma control and asthma outcomes in these patients. We have shown that regular inhaled corticosteroid therapy, regular long-acting b-agonist therapy, and specialty care are associated with improved outcomes in our population We have also shown that inhaled corticosteroid monotherapy is more cost effective than other forms of controller monotherapy in our patients 31 and that stepping up therapy (defined based on an administrative data algorithm) is associated with reduced subsequent asthma impairment based on SABA canister dispensings. 32 However, we have not yet specifically shown that interventions in patients identified by the markers of high risk or uncontrolled disease described above are associated with improved outcomes in those patients. Such studies would be welcome. The medication ratio measure could be used to compare health plans (eg, percentage of 2-year HEDIS-defined persistent asthmatic patients with a ratio >_0.5), such that best practices from high-performing plans could be shared with other plans. In addition, inreach to individual providers with higher proportions of patients with persistent asthma who have low ratios could potentially improve the provider s prescribing habits or clinical approach to patients. As above, although it would be hoped that this provider-oriented use of the medication ratio measure would improve asthma outcomes for patients, such an effect remains to be demonstrated. One limitation of using administrative and survey data, as described above, is that this approach does not directly consider pulmonary function, which is not routinely captured in these venues. The diagnosis of asthma in these studies is usually based on physician-diagnosed asthma (based on encounter coding or patient report) rather than documented reversible airway obstruction. However, identification of physician-diagnosed asthma has been shown to be a valid way to identify asthmatic patients in epidemiologic studies. 33 Having pulmonary function data would still be desirable because prior studies have shown that FEV 1 is independently associated with future asthma exacerbations, even after accounting for other significant demographic, environmental, allergic, and asthma severity risk factors. 34,35 As electronic medical records become increasingly available and integrated with other electronic data, pulmonary function data should be able to be included in future computer-based population assessments. Although the methods described in this article were designed to be applied to large populations, there are some potential applications to individual or group practices. Pharmacy data are increasingly available to all practitioners, which could allow use of the b-agonist control scale, the ratio measure, and the pharmacy-based risk assessment by individual practitioners. Specifically, practitioners could reach out to patients in their practice whose pharmacy data suggest uncontrolled asthma (>6 b-agonist canisters dispensed in a year), undertreated asthma (medication ratio <0.5), or higher-risk asthma (level 4 in the 4- level algorithm, Table I). Individual physicians could also make use of survey data (eg, the ACT) administered by electronic media, mail, or telephone to evaluate both their patients current level of impairment and implications regarding future risk without requiring an in-person visit. We thus hope that the approaches described in this article could benefit patients with asthma cared for in individual practices, as well as in large health plans. REFERENCES 1. Centers for Disease Control and Prevention. Asthma. Available at: gov/nchs/fastats/asthma.htm. Accessed September 4, Kamble S, Bharmal M. Incremental direct expenditures of treating asthma in the United States. J Asthma 2009;46: Fuhlbrigge A, Reed ML, Stempel DA, Ortega HO, Fanjing K, Stanford RH. The status of asthma control in the U.S. adult population. Allergy Asthma Proc 2009;30: Liu AH, Gilsenan AW, Stanford RH, Lincourt W, Ziemiecki R, Ortega H. Status of asthma control in pediatric primary care: results from the Pediatric Asthma Control Characteristics and Prevalence Survey Study (ACCESS). J Pediatr 2010;157: Davies TJ, Bunn WB 3rd, Fromer L, Gelfand EW, Colice GL. A focus on the asthma HEDIS measure and its implications for clinical practice. Manag Care Interface 2006;19: National Asthma Education and Prevention Program expert panel report 3: guidelines for the diagnosis and management of asthma. Summary report J Allergy Clin Immunol 2007;120(suppl):S National Committee for Quality Assurance: HEDIS technical specifications. Washington (DC): National Committee for Quality Assurance; Mosen DM, Macy E, Schatz M, Mendoza G, Stibolt TB, McGaw J, et al. How well do the HEDIS asthma inclusion criteria identify persistent asthma? Am J Manag Care 2005;11: Schatz M, Zeiger RS, Yang SJ, Chen W, Crawford WW, Sajjan SG, et al. Persistent asthma defined using HEDIS versus survey criteria. Am J Manag Care 2010;16: e Schatz M, Zeiger RS, Vollmer WM, Mosen D, Apter AJ, Stibolt TB, et al. Validation of a b-agonist long term control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006;117: Schatz M, Zeiger RS, Drane A, Harden K, Cibildak A, Oosterman JE, et al. Reliability and predictive validity of the Asthma Control Test administered by
5 VOLUME 128, NUMBER 2 SCHATZ AND ZEIGER 277 telephone calls using speech recognition technology. J Allergy Clin Immunol 2007; 119: Schatz M, Nakahiro R, Jones CH, Roth RM, Joshua A, Petitti D. Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care 2004;10: Schatz M, Zeiger RS, Vollmer WM, Mosen D, Apter AJ, Stibolt TB, et al. Development and validation of a medication intensity scale derived from computerized pharmacy data that predicts emergency hospital utilization for persistent asthma. Am J Manag Care 2006;12: Schatz M, Mosen D, Apter AJ, Zeiger RS, Vollmer WM, Stibolt TB, et al. Relationship of validated psychometric tools to subsequent medical utilization for asthma. J Allergy Clin Immunol 2005;115: Schatz M, Zeiger RS, Mosen D, Vollmer WM. Asthma-specific quality of life and subsequent asthma emergency hospital care. Am J Manag Care 2008;14: Schatz M, Zeiger RS, Yang S-J, Chen W, Crawford W, Sajjan S et al. The relationship of asthma impairment determined by psychometric tools to subsequent asthma exacerbations. Abstract presented at American Thoracic Society International Conference, May Fuhlbrigge A, Carey VJ, Adams RJ, Finkelstein JA, Lozano P, Weiss ST, et al. Evaluation of asthma prescription measures and health system performance based on emergency department utilization. Med Care 2004;42: Berger WE, Legoretta AP, Blaiss MS, Schneider EC, Luskin AT, Stempel DA, et al. The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol 2004; 93: Schatz M, Stempel D. Asthma quality-of-care measures using administrative data: relationships to subsequent exacerbations in multiple databases. Ann Allergy Immunol 2008;101: Yong PL, Werner RM. Process quality measures and asthma exacerbations in the Medicaid population. J Allergy Clin Immunol 2009;124: Schatz M, Nakahiro R, Crawford W, Mendoza G, Mosen D, Stibolt TB. Asthma quality-of-care markers using administrative data. Chest 2005;128: Schatz M, Zeiger RS, Vollmer WM, Mosen D, Mendoza G, Apter AJ, et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 2006;130: Schatz M, Zeiger RS, Yang SJ, Chen W, Crawford WW, Sajjan SG, et al. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. Am J Manag Care 2010;16: Mosen DM, Schatz M, Gold R, Mularski RA, Wong WF, Bellows J. Medication use, emergency hospital utilization, and quality of life outcomes by race/ethnicity among adults with asthma. Am J Manag Care 2010;16: Apter AJ, Casillas AM. Eliminating health disparities: what have we done and what do we do next? J Allergy Clin Immunol 2009;123: Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use and mortality: United States Natl Health Stat Rep 2011;32: Talreja N, Baptist AP. Effect of age on asthma control: results from the National Asthma Survey. Ann Allergy Asthma Immunol 2011;106: Schatz M, Cook EF, Nakahiro R, Petitti D. Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma. J Allergy Clin Immunol 2003;111: Schatz M, Zeiger RS, Mosen D, Apter AJ, Vollmer WM, Stibolt TB, et al. Improved asthma outcomes from allergy specialist care: a population-based cross sectional analysis. J Allergy Clin Immunol 2005;116: Schatz M, Zeiger RS, Vollmer WM, Mosen D, Cook EF. Determinants of future long term asthma control. J Allergy Clin Immunol 2006;118: Zeiger RS, Hay JW, Contreras R, Chen W, Quinn VP, Seal B, et al. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol 2008;121: , e Zeiger RS, Schatz M, Li Q, Zhang F, Purdum AS, Chen W. Step-up care improves impairment in uncontrolled asthma: Administrative data study. Am J Manag Care 2010;16: Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires: a literature review. Chest 1993;104: Fuhlbrigge AL, Kitch BT, Paltiel AD, Kuntz KM, Neumann PJ, Dockery DW, et al. FEV 1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001;107: Osborne ML, Pedula KL, O Hollaren M, Ettinger KM, Stibolt T, Buist AS, et al. Assessing future need for acute care in adult asthmatics. The Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007;132:
Asthma is a common chronic medical condition that is associated
Relationship of Asthma Control to Asthma Exacerbations Using Surrogate Markers Within a Managed Care Database Michael Schatz, MD, MS; Robert S. Zeiger, MD, PhD; Su-Jau T. Yang, PhD; Wansu Chen, MS; William
More informationAsthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care
Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Michael Schatz, MD, MS Allergy Department Kaiser Permanente, San Diego, CA Constructs
More informationAsthma represents a significant burden to the healthcare system.
n clinical n Predicting Asthma Outcomes in Commercially Insured and Medicaid Populations Richard H. Stanford, PharmD, MS; Manan B. Shah, PharmD, PhD; Anna O. D Souza, BPharm, PhD; and Michael Schatz, MD,
More informationProcess quality measures and asthma exacerbations in the Medicaid population
Process quality measures and asthma exacerbations in the Medicaid population Pierre L. Yong, MD, MPH, a,b,c,d,e and Rachel M. Werner, MD, PhD a,d Philadelphia, Pa Background: Asthma quality assessment
More informationHealth care education, delivery, and quality
Relationships among quality of life, severity, and control measures in asthma: An evaluation using factor analysis Michael Schatz, MD, MS, a David Mosen, PhD, e Andrea J. Apter, MD, MSc, f Robert S. Zeiger,
More informationMichael S. Blaiss, MD
Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine Division of Clinical Immunology and Allergy University of Tennessee Health Science Center Memphis, Tennessee Speaker s Bureau: AstraZeneca,
More informationAdherence to asthma controller medication regimens
Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta
More informationAsthma is the most common chronic illness of childhood and
Identifying High-risk Asthma With Utilization Data: A Revised HEDIS Definition Antonia V. Bennett, MA; Paula Lozano, MD; Laura P. Richardson, MD; Elizabeth McCauley, PhD; and Wayne J. Katon, MD Objective:
More informationDetroit: The Current Status of the Asthma Burden
Detroit: The Current Status of the Asthma Burden Peter DeGuire, Binxin Cao, Lauren Wisnieski, Doug Strane, Robert Wahl, Sarah Lyon Callo, Erika Garcia, Michigan Department of Health and Human Services
More informationSeverity assessment in asthma: An evolving concept
Severity assessment in asthma: An evolving concept Mary K. Miller, MS, a Charles Johnson, MBChB, a Dave P. Miller, MS, b Yamo Deniz, MD, a Eugene R. Bleecker, MD, c and Sally E. Wenzel, MD, d for the TENOR
More informationOverweight/Obesity and Risk of Seasonal Asthma Exacerbations
Original Article Overweight/Obesity and Risk of Seasonal Asthma Exacerbations Michael Schatz, MD, MS a, Robert S. Zeiger, MD, PhD a, Feng Zhang, MS b, Wansu Chen, MS b, Su-Jau Yang, PhD b, and Carlos A.
More informationASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION
Online Supplement for: ASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION METHODS Population The Northwest Region of Kaiser Permanente (KPNW) is a large, federally qualified,
More informationThe National Asthma Education and Prevention Program s
Long-Acting b-agonist Among Children and Adults With Asthma Elizabeth A. Wasilevich, PhD, MPH; Sarah J. Clark, MPH; Lisa M. Cohn, MS; and Kevin J. Dombkowski, DrPH Managed Care & Healthcare Communications,
More informationCHAPTER 5. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma
CHAPTER 5 Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma Victor van der Meer, Henk F. van Stel, Moira J. Bakker, Albert C. Roldaan, Willem
More informationAssessing Primary Care Physician s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-Up
The Open Respiratory Medicine Journal, 2010, 4, 9-14 9 Assessing Primary Care Physician s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-Up Open Access William Lincourt *,1, Richard
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationThe association of obesity and asthma severity and control in children
The association of obesity and asthma severity and control in children Kenneth B. Quinto, MD, MPH, a Bruce L. Zuraw, MD, a,b Kwun-Yee T. Poon, c Wansu Chen, c Michael Schatz, MD, MS, a,d and Sandra C.
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationUsing an Asthma Control Questionnaire and Administrative Data To Predict Health-Care Utilization*
Original Research ASTHMA Using an Asthma Control Questionnaire and Administrative Data To Predict Health-Care Utilization* Dawn Peters, PhD; Chuhe Chen, PhD; Leona E. Markson, ScD; Felicia C. Allen-Ramey,
More informationORIGINAL INVESTIGATION. Compliance With National Asthma Management Guidelines and Specialty Care
ORIGINAL INVESTIGATION Compliance With National Asthma Management Guidelines and Specialty Care A Health Maintenance Organization Experience Antonio P. Legorreta, MD, MPH; Jennifer Christian-Herman, PhD;
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More information2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64)
2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy Gender: M F Patient Insured - Traditional
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN
More informationEffect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma
Effect of asthma on health care costs among asthmatic patients with moderate and severe persistent asthma Jasmina I. Ivanova, MA, a Rachel Bergman, BA, a Howard G. Birnbaum, PhD, b Gene L. Colice, MD,
More informationEvaluation of Asthma Management in Middle EAst North Africa Adult population
STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Pediatric Asthma: Assessment & Control August 2, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Pediatric Asthma: Assessment & Control August 2, 2017 12:00pm 1:00pm Allyson S. Larkin, MD Assistant Professor of Pediatrics
More informationSetting The setting was the community. The economic study was carried out in New Jersey, USA.
Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy Luskin A, Bukstein D, Kocevar V S, Yin D D Record Status This
More informationOptimal Asthma Control Data Specifications
Optimal Asthma Control Data Specifications Final Version December 2009: Updated for Population Identification April 2010 MNCM Measure Description Methodology Rationale Composite measure of the percentage
More informationPresented by the California Academy of Family Physicians 2013/California Academy of Family Physicians
Family Medicine and Patient-Centered Asthma Care Presented by the California Academy of Family Physicians Faculty: Hobart Lee, MD Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationHealth Policy Research Brief
Health Policy Research Brief July 2008 Uncontrolled Asthma Means Missed Work and School, Emergency Department Visits for Many Californians Ying-Ying Meng, Susan H. Babey, Theresa A. Hastert, Christina
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationThe Safety of Asthma and Allergy Medications in Pregnancy: New Horizons
The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons Jennifer Namazy, MD Division of Allergy Scripps Clinic, San Diego Michael Schatz, MD, MS Department of Allergy Kaiser Permanente,
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationJuly, Years α : 7.7 / 10, Years α : 11 / 10,000 < 5 Years: 80 / 10, Reduce emergency department visits for asthma.
What are the Healthy People 1 objectives? July, 6 Sponsored by the U.S. Department of Health and Human Services, the Healthy People 1 initiative is a comprehensive set of disease prevention and health
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationAsthma Among Minnesota Health Care Program Beneficiaries
Asthma Among Minnesota Health Care Program Beneficiaries A JOINT REPORT FROM THE MINNESOTA DEPARTMENT OF HEALTH AND THE MINNESOTA DEPARTMENT OF HUMAN SERVICES November 2018 Asthma Among Minnesota Health
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationAsthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives
Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives Camilla Boslev Bårnes MD and Charlotte Suppli Ulrik MD DMSc Introduction Methods Review of the Literature Adherence
More information2012 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members
2012 Chronic Respiratory Program Evaluation Our mission is to improve the health and quality of life of our members 2012 Chronic Respiratory Program Evaluation Program Title: Chronic Respiratory Program
More information2017 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members
2017 Chronic Respiratory Program Evaluation Our mission is to improve the health and quality of life of our members 2017 Chronic Respiratory Program Evaluation Program Title: Chronic Respiratory Program
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationA View of Asthma in Oregon
A View of Asthma in Oregon Volume I Issue 2 April 22 In this Issue Disparities in Asthma for African Americans... 1 Disparities in Asthma Hospitalizations and ED Visits for African Americans... 2 Disparities
More informationStructural Equation Modeling of Health Literacy and Medication Adherence by Older Asthmatics
Structural Equation Modeling of Health Literacy and Medication Adherence by Older Asthmatics Alex Federman, MD, MPH Division of General Internal Medicine Icahn School of Medicine at Mount Sinai New York,
More informationEffects on Resource Utilization of Adding Salmeterol in Combination or Separately to Inhaled Corticosteroids
RESEARCH Effects on Resource Utilization of Adding Salmeterol in Combination or Separately to Inhaled Corticosteroids JAMES CHAN, PharmD, PhD; RITA L. HUI, PharmD, MS; and MICHELE M. SPENCE, PhD ABSTRACT
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationAsthma drug ratios and exacerbations: claims data from universal health coverage systems
ORIGINAL ARTICLE ASTHMA Asthma drug ratios and exacerbations: claims data from universal health coverage systems Laurent Laforest 1, Idlir Licaj 1, Gilles Devouassoux 2,Gérard Chatte 3, Jennifer Martin
More informationAsthma Beliefs and Literacy in the Elderly. Melissa Martynenko, MPA, MPH ABLE Project Manager Mount Sinai School of Medicine
Beliefs and Literacy in the Elderly Melissa Martynenko, MPA, MPH ABLE Project Manager Mount Sinai School of Medicine Health Literacy Annual Research Conference Bethesda, MD October 22, 2012 Background:
More informationCME/CE POSTTEST CME/CE QUESTIONS
CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education
More informationFour of 10 patients with asthma suffer moderate REVIEW DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA. Michael S. Blaiss, MD ABSTRACT
DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA Michael S. Blaiss, MD ABSTRACT The differences between clinical trials and clinical practice often create difficulty for generalizing results of controlled
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationNational Trends in Ambulatory Asthma Treatment,
National Trends in Ambulatory Asthma Treatment, 1997 2009 Ashley Higashi, MPH 1, Shu Zhu, MPH 1, Randall S. Stafford, MD, PhD 2, and G. Caleb Alexander, MD, MS 1,3,4,5 1 Section of General Internal Medicine,
More informationAsthma is a highly prevalent and costly
Asthma Treatment Guidelines: How Do We Measure Up? Robert P. Navarro, PharmD Abstract The use of clinical guidelines for the management of asthma can help improve patient outcomes and control costs. This
More informationNucala (mepolizumab) Prior Authorization Protocol
Nucala (mepolizumab) Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationASTHMA What Keeps the Wheeze Away. Dr. Janice Bacon MPHCA Annual Conference June 2016
ASTHMA What Keeps the Wheeze Away Dr. Janice Bacon MPHCA Annual Conference June 2016 ASTHMA Objectives Understand the effects of Asthma on the Pediatric population Understand the effects of Asthma on the
More informationExposure to Indoor Biomass Fuel Pollutants and Asthma Prevalence in Southeastern Kentucky: Results From the Burden of Lung Disease (BOLD) Study
University of Kentucky From the SelectedWorks of David M. Mannino September, 2010 Exposure to Indoor Biomass Fuel Pollutants and Asthma Prevalence in Southeastern Kentucky: Results From the Burden of Lung
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationBridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide
Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Altarum Bridges to Excellence 3520 Green Court, Suite 300 Ann Arbor, MI 48105 bte@altarum.org www.bridgestoexcellence.org
More informationTHE ROLE OF INDOOR ALLERGEN SENSITIZATION AND EXPOSURE IN CAUSING MORBIDITY IN WOMEN WITH ASTHMA
Online Supplement for: THE ROLE OF INDOOR ALLERGEN SENSITIZATION AND EXPOSURE IN CAUSING MORBIDITY IN WOMEN WITH ASTHMA METHODS More Complete Description of Study Subjects This study involves the mothers
More informationGuideline for the Diagnosis and Management of Chronic Childhood Asthma
Guideline for the Diagnosis and Management of Chronic Childhood Asthma Guideline developed by Larry A. Simmons, MD, FAAP, Associate Professor of Pediatrics, Department of Pediatrics, UAMS at Arkansas Children
More informationEncouraging the use of asthma control questionnaires ATAQ and TRACK to improve asthma management and outcomes
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Encouraging the use of asthma control questionnaires ATAQ and TRACK to improve asthma
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2018, Vol. 4, Issue 10, 01-08 Research Article ISSN 2454-2229 Firas et al. WJPLS www.wjpls.org SJIF Impact Factor: 5.088 ASTHMA CONTROL Dr. Yaarub Madhloom Abbas 1, Dr. Firas Raad Shihab* 2 and
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More informationBUKSTEIN, MD; ALLAN LUSKIN, MD; SHIVA G. SAJJAN,
RESEARCH Administrative Claims Analysis of Asthma-Related Health Care Utilization for Patients Who Received Inhaled Corticosteroids With Either Montelukast or Salmeterol as Combination Therapy FELICIA
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationMethods to Diagnose Adherence Status
Methods to Diagnose Adherence Status March 4, 2014 Andrew G Weinstein MD Associate Clinical Professor Pediatrics Jefferson Medical College President, Adherence Management Systems Disclosures President,
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationHealth care education, delivery, and quality. Influence of patients characteristics and disease management on asthma control
Influence of patients characteristics and disease management on asthma control Laurent Laforest, MD, PhD, a Eric Van Ganse, MD, PhD, a Gilles Devouassoux, MD, PhD, b Jean Bousquet, MD, PhD, c Stephanie
More informationImproving Asthma Care: An Update for Managed Care Achieving Optimal Outcomes
Improving Asthma Care: An Update for Managed Care Achieving Optimal Outcomes Aidan A. Long, MD Clinical Director, Allergy and Immunology Massachusetts General Hospital Faculty Information Presenter: Aidan
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationRacial and Socioeconomic Disparities in Appendicitis
Racial and Socioeconomic Disparities in Appendicitis Steven L. Lee, MD Chief of Pediatric Surgery, Harbor-UCLA Associate Clinical Professor of Surgery and Pediatrics David Geffen School of Medicine at
More informationASTHMA; COMPARISON OF SALMETEROL /FLUTICASONE PROPIONATE AND FORMOTEROL / BUDESONIDE IN PERSISTENT ASTHMA
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4443 ORIGINAL PROF-4443 ASTHMA; COMPARISON OF SALMETEROL /FLUTICASONE PROPIONATE AND FORMOTEROL / BUDESONIDE IN PERSISTENT ASTHMA 1. MBBS PGR, Medicine
More informationAsthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?
Registrar: LG PR RS Topic Asthma and COPD Asthma Tutorial Trainer MRW Date of Tutorial 18 th Jan 2007 Objectives of the tutorial How to diagnose What investigations and when Treatment guidelines QoF Criteria
More informationOverview of Asthma Disease Management
Overview of Asthma Disease Management Asthma can be one of the most daunting challenges within managed care. Although managed care organizations have been successful in controlling the per capita expenditures
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationOffice Asthma Care: Practical Elements of Asthma Management. Learning Objectives. Diagnosis
Office Asthma Care: Practical Elements of Asthma Management Pri-Med West Annual Conference March 29, 2014 Anaheim, CA Sande Okelo, MD, PhD, University of California Los Angeles sokelo@mednet.ucla.edu www.uclahealth.org/pedspulmonology
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationCHRONIC disease reaps a considerable
J Ambulatory Care Manage Vol. 30, No. 1, pp. 21 29 c 2007 Lippincott Williams & Wilkins, Inc. Is Patient Activation Associated With Outcomes of Care for Adults With Chronic Conditions? David M. Mosen,
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationWhich asthma patient has allergic airway inflammation?
Which asthma patient has allergic airway inflammation? C o n t r o l l i n g A l l e r g i c A s t h m a Several underlying diseases can present symptoms similar to asthma. Therefore, a correct diagnos
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationTrends in Allergic Conditions Among Children: United States,
Trends in Allergic Conditions Among Children: United States, 1997 2011 Kristen D. Jackson, M.P.H.; LaJeana D. Howie, M.P.H., C.H.E.S.; Lara J. Akinbami, M.D. Key findings Data from the National Health
More informationImproving the Management of Asthma to Improve Patient Adherence and Outcomes
Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationCan we achieve GINA guidelines described Asthma control. in a Developing Country? Original Article. Introduction
Can we Achieve GINA Guidelines Described Asthma Control in a Developing Country? Objectives: To assess asthma control and factors predicting good asthma control in our study population. Study Design: It
More informationHow far are we from adhering to national asthma guidelines: The awareness factor
Egyptian Journal of Ear, Nose, Throat and Allied Sciences (2013) 14, 1 6 Egyptian Society of Ear, Nose, Throat and Allied Sciences Egyptian Journal of Ear, Nose, Throat and Allied Sciences www.ejentas.com
More information